Abstract:Abstract The TGF-β signaling pathway governs key cellular processes under physiologic conditions and is deregulated in many pathologies, including cancer. TGF-β is a multifunctional cytokine that acts in a cell- and context-dependent manner as a tumor promoter or tumor suppressor. As a tumor promoter, the TGF-β pathway enhances cell proliferation, migratory invasion, metastatic spread within the tumor microenvironment and suppresses immunosurveillance. Collectively, the pleiotropic nature of TGF-β signaling contributes to drug resistance, tumor escape and undermines clinical response to therapy. Based upon a wealth of preclinical studies, the TGF-β pathway has been pharmacologically targeted using small molecule inhibitors, TGF-β-directed chimeric monoclonal antibodies, ligand traps, antisense oligonucleotides and vaccines that have been now evaluated in clinical trials. Here, we have assessed the safety and efficacy of TGF-β pathway antagonists from multiple drug classes that have been evaluated in completed and ongoing trials. We highlight Vactosertib, a highly potent small molecule TGF-β type 1 receptor kinase inhibitor that is well-tolerated with an acceptable safety profile that has shown efficacy against multiple types of cancer. The TGF-β ligand traps Bintrafusp alfa (a bifunctional conjugate that binds TGF-β and PD-L1), AVID200 (a computationally designed trap of TGF-β receptor ectodomains fused to an Fc domain) and Luspatercept (a recombinant fusion that links the activin receptor IIb to IgG) offer new ways to fight difficult-to-treat cancers. While TGF-β pathway antagonists are rapidly emerging as highly promising, safe and effective anticancer agents, significant challenges remain. Minimizing the unintentional inhibition of tumor-suppressing activity and inflammatory effects with the desired restraint on tumor-promoting activities has impeded the clinical development of TGF-β pathway antagonists. A better understanding of the mechanistic details of the TGF-β pathway should lead to more effective TGF-β antagonists and uncover biomarkers that better stratify patient selection, improve patient responses and further the clinical development of TGF-β antagonists.

Targeting the transforming growth factor-β signaling pathway in human cancer

Transforming Growth Factor Beta Signaling Pathway: A Promising Therapeutic Target For Cancer

Transforming Growth Factor Β Signaling Pathway: A Promising Therapeutic Target for Cancer

Targeting TGF-β Signaling in Cancer.

Exploring the potential of TGFβ as a diagnostic marker and therapeutic target against cancer

A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment

Targeting TGFβ signal transduction for cancer therapy

The Role of TGF-β Signaling Pathways in Cancer and Its Potential as a Therapeutic Target

Targeting transforming growth factor‐β signalling for cancer prevention and intervention: Recent advances in developing small molecules of natural origin

Targeting the TGFβ pathway for cancer therapy

The Dynamic Roles of TGF‐β in Cancer

Novel therapies emerging in oncology to target the TGF-β pathway

Biphasic Role of TGF-β in Cancer Progression: From Tumor Suppressor to Tumor Promotor

Targeting transforming growth factor- signaling for enhanced cancer chemotherapy

Roles of TGF-β Signaling Pathway in Tumor Microenvirionment and Cancer Therapy.

Positive and Negative Effects of TGF-β Signaling Pathways in Carcinogenesis

Targeting transforming growth factor-β signaling for enhanced cancer chemotherapy

TGF-β signaling: critical nexus of fibrogenesis and cancer

Transforming growth factor-beta signaling and tumor angiogenesis.

TGF-beta signal transduction: biology, function and therapy for diseases

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells.